Drugs targeting other genes have not been tested for migraine, but β-nerve growth factor inhibitors (antibodies) that target NGF (fasinumab, tanezumab and fulranumab) are widely studied in the context of various other chronic pain conditions (for example, sciatica, low back pain and abdominal pain; www.ClinicalTrials.gov). The gene discussed is NGF; the disease is Sciatica.